News | December 25, 2025
Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The initiative is focused on a problem that continues to plague cancer outcomes in India
The move strengthens GBL’s clinical-stage presence in the United States
The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Ryght AI tackles these hurdles with its AI Site Twin platform
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
The companies aim to expand treatment options for millions living with metabolic disorders
Subscribe To Our Newsletter & Stay Updated
